Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study
Open Access
- 18 March 2022
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (7) , 1976-1982
Abstract
Context Incidence and awareness of endocrine-related adverse events (ERAE) associated with use of immune checkpoint inhibitors (ICI) has grown with increased ICI use, yet mechanisms for ERAE prediction, surveillance, and development are not well established. Objective We prospectively evaluated the impact of endocrine autoimmunity on ERAE development and overall survival (OS). Methods Adults ≥ 18 years of age prescribed ICI treatment for advanced or metastatic solid tumors and no known active/past endocrine disorders were eligible for enrollment. Thyroid, adrenal, and pancreatic antibodies as well as hormone levels were assessed prior to ICI treatment and at 8 to 9 weeks and 36 weeks after treatment for ERAE in relation to presence and changes in endocrine-specific antibodies, hormone levels, and OS. Results Sixty patients were enrolled and ERAE were detected in 14 (23.3%), with a median onset of 52 days (IQR, 38.5-71.5) after first ICI dose. Hypothyroidism occurred in 12 (20%) patients, and 2 (3.33%) patients developed hypophysitis. Diabetes and primary adrenal insufficiency were not observed. Antibodies were detected in 14 patients (11 at baseline, 3 developed during follow-up) and their presence was significantly associated with ERAE (R2 59.3%, P < 0.001). Thyroid peroxidase antibody (20%) and thyroid-stimulating immunoglobulin (3.3%) were most common, and anti-GAD was present in 1 patient. The presence of ERAE was associated with a more favorable OS (P = 0.001). Conclusion Endocrine-specific autoantibodies play an important role in ERAE pathogenesis and may serve as predictive markers for early identification and treatment of ICI-induced endocrinopathies.Keywords
Funding Information
- Clinical Scholars Grant
- National Center for Advancing Translational Sciences
- Clinical and Translational Science Institute, University of California, Los Angeles (UL1TR001881)
- National Institutes of Health (T32DK007770)
This publication has 38 references indexed in Scilit:
- Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone ReplacementThyroid®, 2014
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic MelanomaThe Journal of Clinical Endocrinology & Metabolism, 2014
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking AntibodyScience Translational Medicine, 2014
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionEndocrine-Related Cancer, 2014
- Endocrine Side Effects Induced by Immune Checkpoint InhibitorsThe Journal of Clinical Endocrinology & Metabolism, 2013
- Human conditions of insulin-like growth factor-I (IGF-I) deficiencyJournal of Translational Medicine, 2012
- Association of Ipilimumab Therapy for Advanced Melanoma with Secondary Adrenal Insufficiency: A Case SeriesEndocrine Practice, 2012
- Thyrotropin and Thyroid Antibodies as Predictors of Hypothyroidism: A 13-Year, Longitudinal Study of a Community-Based Cohort Using Current Immunoassay TechniquesThe Journal of Clinical Endocrinology & Metabolism, 2010
- Thyroid Status, Disability and Cognitive Function, and Survival in Old AgeJAMA, 2004
- Postpartum Autoimmune Thyroid Syndrome.Endocrine Journal, 2000